Khiron Life Sciences Corp., has successfully exported its registered cannabis strains in the form of live clones to Europe.
This achievement makes the company the very first in Columbia to export such clones to the continent.
Khiron is executing on an asset light growth strategy in Europe by working with contract manufacturing and distribution partners to accelerate production and delivery of EU-GMP certified medical cannabis products.
The company is expecting to grow its existing European offering by introducing branded extracts and dried flower products, based on those already distributed in Colombia and Peru, with over 13,000 prescriptions written to date.
Tejinder Virk, President of Khiron Europe, stated, “Our experience in Colombia and Europe tells us that doctors require solid clinical evidence to feel confident that medical cannabis is the right treatment for their patients. By exporting our Colombian cannabis strains, we will be able to bring our Latin American extracts to European patients, resulting in wider choices for doctors, and safer, more efficacious patient outcomes. Additionally, this import provides an opportunity to accelerate speed to market, optimize our global diversified supply chain and maximize economics.”
To date, the company’s medicinal cannabis products have shown strong evidence as alternative treatments for different ailments including chronic pain, anxiety, insomnia, depression, epilepsy, migraines, and Parkinson’s Disease.
